Amir Harari, MD
Endocrinology, Diabetes & Metabolism · Scottsdale, AZNPI 1578537353
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $303,295 of the $361,322 with a category attached, or 83.9%. Novo Nordisk accounts for 70.8% of it on its own, with 59 other manufacturers making up the rest. Among endocrinology, diabetes & metabolism clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,260 payments — averaging $286.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$256K
- Abbott$29K
- Lilly USA, LLC$26K
- Ascensia Diabetes Care US Inc.$20K
- Johnson & Johnson$10K
- Senseonics, Incorporated$8K
- plus $12K from 54 others
What the payments were for
- Consulting fees$14,1884%
- Speaking & faculty fees$303,29584%
- Travel & lodging$19,9986%
- Food & beverage$23,4166%
- Education$4260%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$116,553
- RYBELSUS$104,803
- HUMULIN$22,475
- FREESTYLE LIBRE 3$16,599
- Tresiba$16,171
- EVERSENSE E3 SENSOR KIT - RETAIL$10,445
- INVOKANA$9,322
- Eversense$7,942
- FreeStyle Libre 2$7,449
- EVERSENSE E3 SMART TRANSMITTER KIT$6,000
- Xultophy 100/3.6$2,212
- FreeStyle Libre$2,063
- Korlym$2,053
- FreeStyle Libre Pro$1,994
- TRULICITY$880
- iLet Bionic Pancreas$516
- Reltone 200 Mg$500
- GLYCATE$500
- Reltone 400 Mg$500
- ISTURISA$313
How this compares
$361,322 in reported general payments places this provider in the 95th percentile of 148 endocrinology, diabetes & metabolism providers in Arizona.
See all endocrinology, diabetes & metabolism providers in Arizona →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 247 | $333,317 |
| MounjaroTirzepatide | 126 | $160,605 |
| Tresiba Flextouch U-200Insulin Degludec | 95 | $92,059 |
| JardianceEmpagliflozin | 74 | $77,251 |
| TrulicityDulaglutide | 53 | $75,780 |
| FarxigaDapagliflozin Propanediol | 37 | $38,965 |
| Tresiba Flextouch U-100Insulin Degludec | 57 | $38,325 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 23 | $30,058 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 44 | $27,732 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 24 | $20,361 |
| Lyumjev Kwikpen U-100Insulin Lispro-Aabc | 12 | $14,489 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 108 | $13,552 |
| Humalog Kwikpen U-100Insulin Lispro | 41 | $12,725 |
| Novolog FlexpenInsulin Aspart | 51 | $12,486 |
| SynthroidLevothyroxine Sodium | 130 | $11,959 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $255,722 | $335,533263 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $26,294 | $245,482226 claims |
| Boehringer IngelheimJardiance | $462 | $77,25174 claims |
| AstraZenecaFarxiga | $620 | $38,96537 claims |
| AbbVieSynthroid | $491 | $11,959130 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $272 | $7,881784 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 148 endocrinology, diabetes & metabolism providers in Arizona.
Other endocrinology, diabetes & metabolism in Scottsdale
- Kristina BlohmScottsdale$220K
- Andrea FerencziScottsdale$132K
- Sreedevi ReddyScottsdale$28K
- Grace Zlaket MattaScottsdale$17K
- Heather SaranScottsdale$14K
- Chandana MishraScottsdale$11K
- Vincent LiouScottsdale$10K
- Kimberlee BrontsemaScottsdale$9K
- Dena HaddadScottsdale$8K
- Mercedes RomeroScottsdale$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.